Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17945845 | 0.85 | TNF (0.51) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4513775 | 0.85 | CYP3A4 (0.56) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12074747 | 0.84 | TNF (0.69) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6998015 | 0.84 | TNF (0.73) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17945511 | 0.83 | TNF (0.63) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1773382 | 0.83 | KDM4E (0.58) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7118474 | 0.83 | CYP17A1 (0.55) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12386959 | 0.83 | TNF (0.53) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25454970 | 0.82 | LMNA (0.53) | PRKCZLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20095043 | 0.82 | KDR (0.56) | PRKCZLMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351822-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-08 | — | — | US | disclosed |
| US-20230372515-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH ACTIVATION OF THE MAPK PATHWAY | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20230357714-A1 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-09 | — | — | US | disclosed |
| US-11725185-B2 | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-11471538-B2 | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway | INSERM (Institut National de la Santéet de la Recherche Medicale) (FR) | 2022-10-18 | — | — | US | disclosed |
| US-20210062145-A1 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-03-04 | — | — | US | disclosed |
| EP-3732285-A1 | STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO | Tract Pharmaceuticals, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20190262343-A1 | WOUND HEALING USING BRAF INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
| EP-3471701-A1 | WOUND HEALING USING BRAF INHIBITORS | The Regents of the University of California (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2018146253-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH ACTIVATION OF THE MAPK PATHWAY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-08-16 | — | — | WO | disclosed |
| WO-2010032986-A3 | NOVEL 5-(4-AMINOPHENYL)-ISOQUINOLINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PROPHYLAXIS AND TREATMENT OF MEDICAL CONDITION INDUCED BY RAF KINASE HYPERACTIVITY | 주식회사 이큐스팜 (KR) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010032986-A2 | NOVEL 5-(4-AMINOPHENYL)-ISOQUINOLINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PROPHYLAXIS AND TREATMENT OF MEDICAL CONDITION INDUCED BY RAF KINASE HYPERACTIVITY | 주식회사 이큐스팜 (KR) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032986-A2 | NOVEL 5-(4-AMINOPHENYL)-ISOQUINOLINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PROPHYLAXIS AND TREATMENT OF MEDICAL CONDITION INDUCED BY RAF KINASE HYPERACTIVITY | 주식회사 이큐스팜 (KR) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032986-A2 | NOVEL 5-(4-AMINOPHENYL)-ISOQUINOLINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PROPHYLAXIS AND TREATMENT OF MEDICAL CONDITION INDUCED BY RAF KINASE HYPERACTIVITY | 주식회사 이큐스팜 (KR) | 2010-03-25 | — | — | WO | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1689717-B1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LTD (GB) | 2007-12-26 | — | — | EP | disclosed |
| EP-1689717-A1 | SUBSTITUTED ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049576-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262343-A1 | WOUND HEALING USING BRAF INHIBITORS | BRAF, NRAS, RAF1 | PRKCZ 1822/4885LMNA 4510/4885CYP1A2 3539/4885 |
| US-20090291949-A1 | SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS | HRH4, NR1H2, NR1H3 | PRKCZ 4826/4885LMNA 1950/4885CYP1A2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.